{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'Protocol activity (visits 1 week)', 'Treatment Period: Day 1 through Week 28', 'Screening', 'Follow-up Visit', '(Note: All visit timings are relative to Day 1)', 'Week -41', 'Screening', 'Day 1', 'Week 2', 'Full study visit', 'Abbreviated study visit', '(4 weeks post', 'Week 28', 'Unscheduled', 'Week -2', 'Week 4, 16', 'Week 8, 12, 20, 24', 'treatment)', 'Genetic Sample 14', 'X', '1.', 'SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ECG, electrocardiogram; FSH, follicle stimulating hormone; FRP, Females of Reproductive Potential;', 'WOCBP, woman of childbearing potential; hCG, human chorionic gonadotropin; UIBC, unsaturated iron binding capacity; hsCRP, high sensitivity C-reactive protein, serious', 'adverse events (SAEs); ADPKD autosomal dominant polycystic kidney disease. If participants does not meet eligibility criteria during/after week -4, then week -2 visit should not be', 'conducted.', '2. Only history related to medical and hospitalization will be re-checked on Day 1 to confirm eligibility prior to randomization.', '3.', 'SBP/DBP, HR (single readings unless otherwise indicated)', '4.', 'ECG can be conducted at Week -2 visit or at Day 1 prior to randomization.', '5.', 'Ultrasound of the kidneys and adrenal glands must be performed prior to randomization. The screening period may be extended up to 2 weeks if needed. A documented', 'ultrasound of the kidneys within the 6 months prior to screening may be used to assess entry criteria provided the size and cyst category has been reported. If a more sensitive', 'imaging study [e.g., magnetic resonance imaging (MRI), computed tomography (CT)] has been performed within this timeframe and a report is available, this may be used in place', 'of the ultrasound. See Section 9.5.4.', '6.', 'Record historical and current anemia therapy in eCRF, if applicable.', '7.', 'See details on rescue in Section 7.7.2.', '8.', 'Repeat pregnancy test prior to study treatment re-administration if it is interrupted for >7 days and there was also a lapse in contraceptive use, regardless of the reason for the', 'interruption. If a participant becomes post-menopausal (as defined in Section 12.4) during the study, pregnancy tests are no longer required.', '9.', 'Participant are eligible for randomization if the initial HemoCue Hgb assessment is from 8.5 to 10.0 g/dL. Repeat a HemoCue Hgb assessment using the same sample and use', 'the average of the two values for randomization only if the initial assessment is from 10.1 to 10.3 g/dL, or if the initial assessment is from 8.2 to 8.4 g/dL. If the average Hgb is also', 'from 10.1 to 10.3 or from 8.2 to 8.4 g/dL then another HemoCue Hgb assessment can be performed using a new blood sample on the Day 1 visit date. All HemoCue Hgb', 'assessments, starting after Day 1 to end of treatment visit, should be conducted at the end of the study visit, only prior to study medication or rescue medication dispensation.', '10.', 'See details on hematology, clinical chemistry and other laboratory assessments in Section 9.5.5.', '11. Ferritin, total iron and UIBC will be assessed at Week 16, but not at Week 4.', '12. Participants will be provided a Visit Reminder Card (at Day 1) along with the verbal instruction to promptly inform site staff of any health changes. Health changes include new', 'symptoms or medical problems (e.g., pregnancy, hospitalizations) and changes in medication', '13. Only SAEs assessed as related to study participation or a GSK product are collected at this visit. See Section 9.3.1 for additional details', '14. Informed consent for optional Genetic research should be obtained before collecting a sample. To minimize potential study bias, the genetic sample should be collected on Day 1.', '15. France sites and participants with history of ADPKD only (to be performed at or after the week 28 study visit or as soon as clinically feasibile prior to the Follow-up visit (see', 'Section 9.5.4) for additional details).', '16. For Argentinian sites only and only in WOCB', '17. New doses of study treatment will be provided to participants starting from Day 1 to week 24 visit as indicated by IRT System. Study treatment may be dispensed at week 2 or', 'unscheduled visit only if indicated by IRT system, otherwise participants should continue on study treatment dispensed at prior study', 'visit.', '14']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Table 2', 'Schedule of Activities for Patient Reported Outcomes and Actigraphy', 'Protocol Activity', 'Treatment Period: Day 1 through Week 28', 'Follow-up', '(visits +1 week)', 'Screening', 'Week -2', 'Day', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Visit', '(Note: All visit timings are relative to Day 1)', 'Week -4', '1', '4', '8', '12', '16', '20', '24', '28', 'Dispense Actigraphy Device', 'X', 'X', 'Actigraphy (wearable)1,5,6', 'X', 'X', 'X', 'X', 'Patient Global Impression of Severity (PGI-S)2,3', 'X', 'X', 'X', 'X', 'X', 'Patient Global Impression of Change (PGI-C)2,3', 'X', 'X', 'X', 'Symptoms of aCKD questionnaire2', 'X', 'X', 'X', 'X', 'X', 'Short Form 36 (SF-36)2,3', 'X', 'X', 'X', 'EuroQol 5 Dimension 5 Level Health Utility', 'Index (EQ-5D-5L) and EuroQol Visual', 'X', 'X', 'X', 'X', 'Analogue Scale (EQ-VAS) 2,3,4', 'Work Productivity and Activity Impairment', 'X', 'X', 'X', 'X', 'Questionnaire (WPAI-ANS-CPV)2,3', 'Healthcare resource utilization (participants-', 'X', 'X', 'reported)', '1. Actigraphy device should be worn for 7 days prior to the study visits indicated in Table 2 and as described in Section 9.7. Data will be downloaded from device during the study visits', 'indicated in Table 2.', '2. Patient reported outcomes questionnaire should be completed as the first assessment, prior to conducting any other visit assessments (e.g. Adverse event assessment, HemoCue', 'Hgb, etc.)', '3. Subjects who are unable to or require assistance to read must not complete the questionnaires', '4. Only in selected countries. See Section 12.8 (Appendix 8).', '5. Sites can contact subjects to wear the actigraphy device 7 days prior to study visit.', '6. All efforts should be made to encourage participation in this activity monitoring assessment. If a participant is unable to take part, the reason should be documented, and they may', 'continue in the study.', '15']\n\n###\n\n", "completion": "END"}